Cancer drugs help the hardest cases of Pompe disease
Kids with Pompe disease fail because of a missing enzyme, GAA, that leads to dangerous sugar build-up, which affects muscles and movement. An enzyme replacement treatment pioneered at Duke University has saved many lives, but some children with Pompe disease produce an immune reaction that blocks the benefits of the life-saving enzyme treatment.
To date there has been no success in eliminating or suppressing this immune response.
Now research led by Duke University Medical Center, with collaborators at other centers, has resulted in successful enzyme replacement therapy for children who were predicted to have or who had the immune reaction blocking the effects of the enzyme therapy. In the past, children with this immune response died despite treatment.
In an article appearing in Genetics in Medicine, the researchers showed that a very low-dose combination of medicines typically used to treat cancer was successful in eliminating or preventing the immune response.
The drugs were rituximab, methotrexate and gammaglobulins a mix of chemotherapeutic drugs and drugs to support the immune system. These drugs were the right mix for children who had Pompe, and who were most likely weren't going to benefit from the enzyme treatment because of their anti-GAA immune response.
"The goal is to get the new combination therapy to the child who is at risk of rejecting the enzyme, before or at the time the enzyme (recombinant human GAA (rhGAA), known as Myozyme) is infused," said senior author Priya Kishnani, M.D., professor of Pediatrics and Medical Genetics at Duke. "If you can get this combination to people early, before they are infused with the enzyme, they will likely have a very good response to the enzyme treatment. Once the body has been exposed to the enzyme treatment, the babies at risk are likely to mount an immune response that blocks the effectiveness of the infused enzyme."
The group at Duke earlier showed the role of the immune response in children with Pompe disease. Once this response occurred, children who were previously doing well failed to benefit from treatment and died.
The researchers in the current study, spread out in centers at Children's Hospitals & Clinics of Minnesota, Medical College of Wisconsin/Children's Hospital of Wisconsin, Sorka Medical Center in Israel and the Evelina Children's Hospital in London, worked together to treat the at-risk babies with the chemotherapy medicines at the time enzyme treatment started or shortly thereafter.
The team at Duke used genetic sequencing to identify the children at risk of enzyme-treatment failure. The experience of the Duke group allowed for identification of these cases early.
Senior author Kishnani said the stakes of failure are very high. "Until now, children with Pompe who make antibodies to the enzyme treatment die or are placed on invasive ventilation by age 27 months," she said. "It is very difficult for families, because some children who initially showed a benefit and were able to walk then started failing once the immune response occurred. It is heartbreaking to watch, not only for family members, but also for the team that cares for the children."
The study examined four children, two who had Pompe and had never been treated and two who were treated, but were failing.
"We have made a difference in the lives of four patients at medical centers around the world," Kishnani said. "All of them have achieved new motor abilities, in distinct contrast with the relentless downhill course of patients who were unable to tolerate the enzyme therapy and would otherwise have died." Some of these children have now been doing well for a number of years, Kishnani said.
Provided by
Duke University Medical Center
-
Treatment discovered for deadly childhood disease
Dec 06, 2006 |
not rated yet |
0
-
Researchers continue 'extraordinary measures' to tackle Pompe disease
Jan 26, 2010 |
not rated yet |
0
-
Late-onset Pompe patients in US begin receiving new therapy
Jun 16, 2010 |
not rated yet |
0
-
Nervous system may be culprit in deadly muscle disease
May 25, 2009 |
not rated yet |
0
-
Enzyme controlling cell death paves way for treatment of brain damage in newborns
Oct 25, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Genetics
May 24, 2013 |
3 / 5 (2) |
0
|
Patenting the human genome
Can human genes be patented? That was the question posed by Alan J. Snyder, vice president and associate provost for research and graduate studies at Lehigh, and Lee Kaplan, scientific director of cellular and molecular genetics ...
Genetics
May 24, 2013 |
4 / 5 (1) |
0
Researchers complete largest genetic sequencing study of human disease
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
Genetics
May 22, 2013 |
4.5 / 5 (4) |
0
|
Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors
University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...
Genetics
May 20, 2013 |
5 / 5 (1) |
0
|
Researchers identify new circadian clock component
Northwestern University scientists have shown a gene involved in neurodegenerative disease also plays a critical role in the proper function of the circadian clock.
Genetics
May 16, 2013 |
3 / 5 (1) |
1
|
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.